Stay updated on Sepofarsen Repeat-dose in LCA10 Clinical Trial
Sign up to get notified when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.

Latest updates to the Sepofarsen Repeat-dose in LCA10 Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4 with no substantive content changes to the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check16 days agoChange DetectedNo additions or deletions affecting the study details page were detected; the content appears unchanged.SummaryDifference0.1%

- Check24 days agoChange DetectedThe new screenshot appears to reflect minor formatting updates to the Study Details page without altering core trial information such as the NCT number, conditions, locations, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check31 days agoChange DetectedAdded a consolidated Locations section listing study sites in Iowa, Minas Gerais, São Paulo, Ontario, and Quebec. Removed the older individual location entries for those regions and the HHS Vulnerability Disclosure link.SummaryDifference0.6%

- Check38 days agoChange DetectedNo significant changes detected between the two screenshots. The page content and structure appear unchanged, including the study overview, eligibility criteria, and locations.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2 on the page.SummaryDifference0.0%

Stay in the know with updates to Sepofarsen Repeat-dose in LCA10 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sepofarsen Repeat-dose in LCA10 Clinical Trial page.